SCHEMBL18017402

SCHEMBL18017402

Cc1ccc([C@@H](C)[C@H]2CC[C@@H](Cc3ccc(C(=O)O)cc3)N2C(=O)OC(C)(C)C)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.35
RXRB P28702 2/20 0.35
HDAC1 Q13547 1/20 0.34
CETP P11597 3/20 0.33
GPR119 Q8TDV5 2/20 0.33
KMT2A Q03164 1/20 0.33
PTGER4 P35408 2/20 0.32
CYP26A1 O43174 1/20 0.32
CYP3A4 P08684 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
ADAM17 P78536 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KCNK3 O14649 1/20 0.32
KCNK9 Q9NPC2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18210794 0.90 PTGER4 (0.35) RXRARXRBHDAC1CETPGPR119
SCHEMBL18017375 0.90 RXRA (0.37) RXRARXRBHDAC1CETPPTGER4
SCHEMBL18017393 0.90 HDAC1 (0.36) RXRARXRBHDAC1CETPGPR119
SCHEMBL18017374 0.90 RXRA (0.37) RXRARXRBHDAC1CETPPTGER4
SCHEMBL18017387 0.88 ADRB3 (0.40) HDAC1GPR119CYP3A4ALDH1A1
SCHEMBL18017400 0.86 CETP (0.34) RXRARXRBHDAC1CETPGPR119
SCHEMBL18017416 0.86 GAA (0.40) RXRARXRBHDAC1CETPGPR119
SCHEMBL18017373 0.86 GAA (0.40) RXRARXRBHDAC1CETPGPR119
SCHEMBL18017381 0.85 PTGER4 (0.42) RXRARXRBGPR119KMT2APTGER4
SCHEMBL18017382 0.85 RXRA (0.38) RXRARXRBKMT2APTGER4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 RXRA 1400/4885RXRB 1020/4885HDAC1 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.